公开(公告)号：US20200163982A1

公开(公告)日：2020-05-28

申请号：US16613082

申请日：2018-05-09

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell

IPC: A61K31/702 ,  A61K9/00 ,  A61K35/745 ,  A61P1/00

Abstract: The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the level of butyrate in the gastro-intestinal tract of the non-infant human, and methods for their use.

公开(公告)号：US20200069709A1

公开(公告)日：2020-03-05

申请号：US16490027

申请日：2018-03-01

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell

IPC: A61K31/702 ,  A61K31/7004 ,  A23L33/125 ,  A61P1/00 ,  A23L33/135

Abstract: The invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans, particularly for increasing the abundance of Bifidobacterium longum and/or Bifidobacterium bifidum in the gut microbiota of non-infant humans.

公开(公告)号：US10314852B2

公开(公告)日：2019-06-11

申请号：US15521582

申请日：2015-10-23

Applicant: Glycom A/S

Inventor： Elise Champion ,  Bruce McConnell ,  Gyula Dekany

IPC: C12P19/18 ,  C12P19/26 ,  A61K31/702 ,  C07H5/06 ,  A61K31/715 ,  A61K31/7016

Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2′-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2′-FL, and a component D, which is lactose when component A is 3-FL, or 2′-FL when component A is DFL, with the proviso that if component B is 2′-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.

公开(公告)号：US20160367577A1

公开(公告)日：2016-12-22

申请号：US15183404

申请日：2016-06-15

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Emma Salomonsson

IPC: A61K31/702 ,  A61K9/00

CPC classification number: A61K31/702 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/2054

Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).

Abstract translation: 本发明涉及一种用于在具有肥胖相关代谢紊乱的患者中稳定或降低胰岛素抵抗的方法，所述方法包括向患者施用有效量的一种或多种人乳寡糖（HMO）。

公开(公告)号：US11998558B2

公开(公告)日：2024-06-04

申请号：US17120881

申请日：2020-12-14

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  David Paul Kronlage

IPC: A61K31/702 ,  A23L33/125 ,  A61P31/04

CPC classification number: A61K31/702 ,  A23L33/125 ,  A61P31/04 ,  A23V2002/00 ,  Y02A50/30 ,  A61K31/702 ,  A61K2300/00

Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.

公开(公告)号：US20230338403A1

公开(公告)日：2023-10-26

申请号：US17798270

申请日：2019-12-06

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Gabriela Bergonzelli Degonda ,  Laurent Favre ,  Laurent Ferrier ,  Clara Lucia

IPC: A61K31/702 ,  A61P1/04 ,  A61K9/48

CPC classification number: A61K31/702 ,  A61P1/04 ,  A61K9/4825

Abstract: The application relates to compositions containing 2′-FL and DFL for use in a method of reducing pain and/or the perception of visceral pain in a non-infant human.

公开(公告)号：US11419884B2

公开(公告)日：2022-08-23

申请号：US16312506

申请日：2017-06-23

Applicant: GLYCOM A/S

Inventor： Nikolay Khanzhin ,  Markus Jondelius Hederos ,  Louise Kristine Vigsnæs ,  Bruce McConnell

IPC: A61K31/702 ,  C12P1/04 ,  A61P31/04 ,  A61K31/7016 ,  C07H1/00 ,  C12P19/04 ,  C12N9/10 ,  A61K31/716 ,  A61K31/7032

Abstract: The present disclosure relates to synthetic mixtures of certain human milk oligosaccharides and uses thereof. Particular mixtures provided herein include: lacto-N-triose II, lacto-N-neotetraose, para-lacto-N-neohexaose, and, optionally, lactose; and lacto-N-triose II, lacto-N-tetraose, para-lacto-N-hexaose II, and, optionally, lactose. These mixtures are useful in the prevention and treatment of viral and bacterial infections.

公开(公告)号：US11304966B2

公开(公告)日：2022-04-19

申请号：US16956511

申请日：2018-12-19

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6′-sialyllactose (6′-SL) and/or lacto-N-tetraose (LNT).

公开(公告)号：US11224605B2

公开(公告)日：2022-01-18

申请号：US16303131

申请日：2017-05-19

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

IPC: A61K31/702 ,  A61P1/00 ,  A61P25/00

Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for treating serotonin and/or tryptophan dysregulation.

公开(公告)号：US11173171B2

公开(公告)日：2021-11-16

申请号：US16820126

申请日：2020-03-16

Applicant: Glycom A/S

Inventor： Elise Champion ,  Bruce McConnell ,  Gyula Dekany

IPC: A61K31/702 ,  C07H3/06 ,  C12P19/14 ,  C12P19/26 ,  C07H1/00 ,  C12P19/00 ,  C07H5/06 ,  C12P19/18 ,  A61P31/04 ,  A61P31/12 ,  A61K31/7016

Abstract: A mixture of human milk oligosaccharides that consists essentially of 3′-O-sialyllactose, a component A which is either 3-O-fucosyllactose or lacto-N-tetraose, a component B which is 3-0-fucosyl-3′-O-sialyllactose when component A is 3-O-fucosyllactose and sialyllacto-N-tetraose a, when component A is lacto-N-tetraose and optionally lactose as a fourth component. The mixtures are made by treating 3′-O-sialyllactose and component A with an α2,3-transsialidase. The mixtures are for use in anti-bacterial and anti-viral compositions, and for promoting the development of Bifidobacterium and Barnesiella.